CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00942734
NCT00942734Phase 2Completed
CompareCT.gov

Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

M.D. Anderson Cancer Center·interventional·Posted Jul 21, 2009·Updated May 1, 2025

In Brief

A Phase 2 clinical trial evaluating Erlotinib and RAD001 for Head And Neck Cancer. Completed, enrolled 49 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead And Neck Cancer
CountriesUnited States
CollaboratorsNovartis, OSI Pharmaceuticals

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 21, 2009
Enrollment StartJul 1, 2009
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.9 years ago

Interventions

Erlotinibdrug

One tablet (150 mg) by mouth every day of each 28 day study cycle.

RAD001drug

1 tablet (5 mg) by mouth every day of each 28 day study cycle.